Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.

Takafumi MieTakashi SasakiTsuyoshi TakedaTakeshi OkamotoChinatsu MoriTakaaki FurukawaYuto YamadaAkiyoshi KasugaMasato MatsuyamaMasato OzakaNaoki Sasahira

Published in: Japanese journal of clinical oncology (2021)

Benefits of erlotinib plus gemcitabine as late-line chemotherapy were limited, particularly with respect to PFS. Development of more effective third-line treatment options is desirable in the future.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
epidermal growth factor receptor
advanced non small cell lung cancer
current status
liver metastases